Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical Cancer
Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Summary
This is a multicenter, open-label phase I/II study in patients with advanced cervical cancer designed to evaluate the safety, tolerability, and preliminary efficacy of ZG005 in combination with Gecacitinib ± bevacizumab.
Official title: A Multicenter, Open-label, Dose-finding and Dose-expansion Phase I/II Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical Cancer
Key Details
Gender
FEMALE
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
120
Start Date
2025-09-23
Completion Date
2027-12
Last Updated
2026-01-05
Healthy Volunteers
No
Conditions
Interventions
ZG005
ZG005 20mg/kg, intravenous infusion(IV), once every 3 weeks (Q3W)
Gecacitinib
Part 1: Cohort A：Gecacitinib is administered continuously until the end of treatment; Cohort B：Gecacitinib is administered continuously from CnD1 to D14, and discontinued from CnD15 to D21；Part 2：Gecacitinib for dose exploratory stage will commence after the Recommended Phase 2 Dose (RP2D) is determined during the dose escalation stage.
Bevacizumab
Bevacizumab 7.5 mg/kg，intravenous infusion(IV), once every 3 weeks (Q3W)
Locations (1)
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China